Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
It offers numerous benefits across the whole body, including for your digestive system
Griveau JF, Le Lannou D (1997) Reactive oxygen species and human spermatozoa: physiology and pathology
By reducing hunger and making it easier to feel full, semaglutide helps people eat less without feeling deprived
Our facility accepts all major insurance plans, handles prior authorizations entirely, and offers telehealth services for your convenience
| Category | Zepbound | Mounjaro | |-----------------------------------|------------------------------------------------|------------------------------------------------| | FDA Approval Indication | Obesity and overweight management (with comorbidities) | Type 2 diabetes management | | Year of FDA Approval | 2023 | 2022 | | Active Ingredient | Tirzepatide | Tirzepatide | | Dose Range | 2.5 mg to 15 mg once weekly | 2.5 mg to 15 mg once weekly | | Primary Clinical Purpose | Weight loss | Blood sugar control | | GLP-1/GIP Activity | Dual agonist (GLP-1 + GIP) | Dual agonist (GLP-1 + GIP) | | Average Weight Loss (in trials) | Up to 22.5% of body weight in SURMOUNT-1 study | Up to 15% of body weight in SURPASS studies | | Insulin Sensitivity Impact | Improves insulin sensitivity in patients with obesity | Improves insulin sensitivity in type 2 diabetes patients | | Delivery Method | Single-use auto-injector pen, subcutaneous injection | Single-use auto-injector pen, subcutaneous injection | | Dosing Frequency | Once weekly | Once weekly | | Manufacturer | Eli Lilly | Eli Lilly | | Common Side Effects | Nausea, vomiting, diarrhea, constipation, decreased appetite | Nausea, vomiting, diarrhea, constipation, decreased appetite | | Insurance Coverage | Variable
